OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

AVN-211, Novel and Highly Selective 5-HT6 Receptor Small Molecule Antagonist, for the Treatment of Alzheimer’s Disease
Alexandre V. Ivachtchenko, Yan Lavrovsky, Yan A. Ivanenkov
Molecular Pharmaceutics (2016) Vol. 13, Iss. 3, pp. 945-963
Closed Access | Times Cited: 30

Showing 1-25 of 30 citing articles:

Therapeutic Targeting of Autophagy
Christina G. Towers, Andrew Thorburn
EBioMedicine (2016) Vol. 14, pp. 15-23
Open Access | Times Cited: 246

Advancements in autophagy perturbations in Alzheimer’s disease: Molecular aspects and therapeutics
Rishika Dhapola, Sneha Kumari, Prajjwal Sharma, et al.
Brain Research (2025) Vol. 1851, pp. 149494-149494
Closed Access | Times Cited: 2

Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders
Ramakrishna Nirogi, Pradeep Jayarajan, Anil Shinde, et al.
Biomolecules (2023) Vol. 13, Iss. 2, pp. 309-309
Open Access | Times Cited: 29

5HT6 Antagonists in the Treatment of Alzheimer’s Dementia: Current Progress
Megan Andrews, Babak Tousi, Marwan N. Sabbagh
Neurology and Therapy (2018) Vol. 7, Iss. 1, pp. 51-58
Open Access | Times Cited: 41

NOVEL HETEROCYCLIC HYBRIDS AS PROMISING SCAFFOLD FOR THE MANAGEMENT OF ALZHEIMER’S DISEASE
Tyagi Alka
International Journal of Pharmacy and Pharmaceutical Sciences (2025), pp. 1-15
Open Access

Past, present, and future of serotonin-targeting therapeutics for Alzheimer’s Disease: perspectives from DNA methylation
Yanzhi Liu, Luca Aquili, Kah-Hui Wong, et al.
Ageing Research Reviews (2025), pp. 102755-102755
Closed Access

Virtual screening-driven discovery of dual 5-HT6/5-HT2A receptor ligands with pro-cognitive properties
Jakub Staroń, Rafał Kurczab, Dawid Warszycki, et al.
European Journal of Medicinal Chemistry (2019) Vol. 185, pp. 111857-111857
Open Access | Times Cited: 35

Understanding How Physical Exercise Improves Alzheimer’s Disease: Cholinergic and Monoaminergic Systems
Boyi Zong, Fengzhi Yu, Xiaoyou Zhang, et al.
Frontiers in Aging Neuroscience (2022) Vol. 14
Open Access | Times Cited: 16

Serotonin Receptors as a Potential Target in the Treatment of Alzheimer’s Disease
Dmitrii V Eremin, Е. М. Кондаурова, Aleksander Ya Rodnyy, et al.
Biochemistry (Moscow) (2023) Vol. 88, Iss. 12-13, pp. 2023-2042
Closed Access | Times Cited: 10

Dual 5-HT6 and D3 Receptor Antagonists in a Group of 1H-Pyrrolo[3,2-c]quinolines with Neuroprotective and Procognitive Activity
Katarzyna Grychowska, Séverine Chaumont‐Dubel, Rafał Kurczab, et al.
ACS Chemical Neuroscience (2019) Vol. 10, Iss. 7, pp. 3183-3196
Open Access | Times Cited: 29

A dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor displays glioprotective and pro-cognitive properties
Vittorio Canale, Katarzyna Grychowska, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112765-112765
Open Access | Times Cited: 22

Effects of the 5-HT 6 receptor antagonist idalopirdine on extracellular levels of monoamines, glutamate and acetylcholine in the rat medial prefrontal cortex
Arne Mørk, Rasmus Vinther Russell, Inge E.M. de Jong, et al.
European Journal of Pharmacology (2017) Vol. 799, pp. 1-6
Closed Access | Times Cited: 23

The selective 5-HT 6 receptor antagonist SLV has putative cognitive- and social interaction enhancing properties in rodent models of cognitive impairment
Natasja de Bruin, Arnold van Loevezijn, Karsten Wicke, et al.
Neurobiology of Learning and Memory (2016) Vol. 133, pp. 100-117
Closed Access | Times Cited: 22

2-Aminoimidazole-based antagonists of the 5-HT6 receptor – A new concept in aminergic GPCR ligand design
Adam S. Hogendorf, Agata Hogendorf, Rafał Kurczab, et al.
European Journal of Medicinal Chemistry (2019) Vol. 179, pp. 1-15
Closed Access | Times Cited: 21

Structure-Based Design and Optimization of FPPQ, a Dual-Acting 5-HT3 and 5-HT6 Receptor Antagonist with Antipsychotic and Procognitive Properties
Paweł Zajdel, Katarzyna Grychowska, Szczepan Mogilski, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13279-13298
Open Access | Times Cited: 17

5-HT6 Receptor Antagonist as an Adjunct Treatment Targeting Residual Symptoms in Patients With Schizophrenia
Morozova Ma, D. S. Burminskiy, George E. Rupchev, et al.
Journal of Clinical Psychopharmacology (2017) Vol. 37, Iss. 2, pp. 169-175
Closed Access | Times Cited: 16

Neuropathic pain-alleviating effects of pyrazole-conjugated arylsulfonamides as 5-HT6 receptor antagonists
Jin Ri Hong, Hyunah Choo, Ghilsoo Nam
Bioorganic & Medicinal Chemistry Letters (2017) Vol. 27, Iss. 17, pp. 4146-4149
Closed Access | Times Cited: 14

Experimental Serotonergic Agents for the Treatment of Schizophrenia
Enrico Capuzzi, Alice Caldiroli, Veronica Ciscato, et al.
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 49-67
Open Access | Times Cited: 11

Targeting 5-HT Is a Potential Therapeutic Strategy for Neurodegenerative Diseases
Cencan Xing, Hongyu Chen, Wangyu Bi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13446-13446
Open Access | Times Cited: 1

In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer’s Disease
Tijana Bojić, Milan Senćanski, Vladimir Perović, et al.
Molecules (2022) Vol. 27, Iss. 9, pp. 2626-2626
Open Access | Times Cited: 7

Structure-activity relationships studies on weakly basic N -arylsulfonylindoles with an antagonistic profile in the 5-HT 6 receptor
Jaime Mella, Francisco Villegas, Cesar Morales‐Verdejo, et al.
Journal of Molecular Structure (2017) Vol. 1139, pp. 362-370
Closed Access | Times Cited: 8

AVN-492, A Novel Highly Selective 5-HT6R Antagonist: Preclinical Evaluation
Alexandre V. Ivachtchenko, Ilya Okun, Vladimir Aladinskiy, et al.
Journal of Alzheimer s Disease (2017) Vol. 58, Iss. 4, pp. 1043-1063
Closed Access | Times Cited: 8

Computational Modeling of Drugs for Alzheimer’s Disease: Design of Serotonin 5-HT6 Antagonists
Ádám A. Kelemen, Stefan Mordalski, Andrzej J. Bojarski, et al.
Neuromethods (2017), pp. 419-461
Closed Access | Times Cited: 5

Rationally designed N-phenylsulfonylindoles as a tool for the analysis of the non-basic 5-HT6R ligands binding mode
Jakub Staroń, Ryszard Bugno, Wojciech Pietruś, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112916-112916
Closed Access | Times Cited: 3

Page 1 - Next Page

Scroll to top